A prospective open label non randomized clinical trial To Evaluate The Safety And efficacy of Endotone polyherbal capsule in treatment of Endometriosis.

Endometriosis is a prevalent disease estimated to affect 10% of women of reproductive age, upto 50% of women with pelvic pain, and 20%-50% of women with reduced fertility. The commonest symptom is pelvic pain, which presents as dysmenorrhea in over 98% of patients with symptomatic endometriosis and non-menstrual pelvic pain. Pelvic pain associated with endometriosis varies greatly in intensity, frequency and duration from patient to patient. Non-menstrual pelvic pain is usually chronic (lasting ≥ 6 months), and it can be intermittent throughout the menstrual cycle or continuous and may present as dull, throbbing, or sharp pain. In addition, the pain related to endometriosis has been shown to impair both work- related and non-work-related daily activities.

For the present study, a polyherbal formulation manufactured by Charak Pharma Pvt. Ltd. will be taken up for the study. The formulation has been standardized after formulating SOPs along with acute toxicity study. The objective of current study is to assess clinical safety and efficacy of the study drug in symptoms associated with endometriosis.